Welcome to the Rosen Laboratory Website!
Ozanimod, discovered in the Rosen and Roberts laboratories, successfully treats Relapsing and Remitting Multiple Sclerosis in a 1346 patient phase 3 clinical trial. This disease-modifying treatment for MS was discovered in the Scripps Research Institute Molecular Libraries Screening Center, funded by the NIH Common Fund grant #5U54 MH084512 to Hugh Rosen.
J. R. Teijaro, S. Studer, N. Leaf, W. B. Kiosses, N. Nguyen, K. Matsuki, H. Negishi, T. Taniguchi, M. B. A. Oldstone, H. Rosen, S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-α autoamplification. Proc. Natl. Acad. Sci. U.S.A. 113, 1351–1356 (2016).
Brilliant results for MS Patients! TSRI compound to be presented at ACTRIMS 2016 Forum, February 18-20th. After 72 weeks, 92% of patients remained on Ozanimod. Efficacy was outstanding with 63% of 1mg patients and 44% of 0.5mg patients showing No Evidence of Disease Activity.